Is it possible to demonstrate that access to new drugs impacts on a country’s survival rates? Last September, the Karolinska report claimed to have done just that. Here, Michel Coleman argues that its conclusions were misleading and unsupported by the data and analysis. In the Debate that follows, the authors respond and health economists and policy advisors offer their views.
Leave a Reply